ATE180834T1 - Antikoagulierende proteine - Google Patents
Antikoagulierende proteineInfo
- Publication number
- ATE180834T1 ATE180834T1 AT91904449T AT91904449T ATE180834T1 AT E180834 T1 ATE180834 T1 AT E180834T1 AT 91904449 T AT91904449 T AT 91904449T AT 91904449 T AT91904449 T AT 91904449T AT E180834 T1 ATE180834 T1 AT E180834T1
- Authority
- AT
- Austria
- Prior art keywords
- factor vii
- modified
- anticoagulant
- wild
- coagulation cascade
- Prior art date
Links
- 239000002506 anticoagulant protein Substances 0.000 title 1
- 102100023804 Coagulation factor VII Human genes 0.000 abstract 7
- 108010023321 Factor VII Proteins 0.000 abstract 7
- 229940012413 factor vii Drugs 0.000 abstract 7
- 239000003146 anticoagulant agent Substances 0.000 abstract 2
- 229940127219 anticoagulant drug Drugs 0.000 abstract 2
- 230000015271 coagulation Effects 0.000 abstract 2
- 238000005345 coagulation Methods 0.000 abstract 2
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108010054265 Factor VIIa Proteins 0.000 abstract 1
- 108010000499 Thromboplastin Proteins 0.000 abstract 1
- 102000002262 Thromboplastin Human genes 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000035602 clotting Effects 0.000 abstract 1
- 229940088598 enzyme Drugs 0.000 abstract 1
- 229940012414 factor viia Drugs 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6437—Coagulation factor VIIa (3.4.21.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Materials For Medical Uses (AREA)
- Saccharide Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47131390A | 1990-01-29 | 1990-01-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE180834T1 true ATE180834T1 (de) | 1999-06-15 |
Family
ID=23871126
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT91904449T ATE180834T1 (de) | 1990-01-29 | 1991-01-25 | Antikoagulierende proteine |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US5288629A (de) |
| EP (1) | EP0521873B1 (de) |
| JP (2) | JP3330932B2 (de) |
| AT (1) | ATE180834T1 (de) |
| AU (1) | AU651573B2 (de) |
| CA (1) | CA2074839C (de) |
| DE (1) | DE69131292T2 (de) |
| WO (1) | WO1991011514A1 (de) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5580560A (en) * | 1989-11-13 | 1996-12-03 | Novo Nordisk A/S | Modified factor VII/VIIa |
| CA2083164A1 (en) * | 1990-05-17 | 1991-11-18 | Mark K. Mercola | Trans-dominant suppressor genes for oligomeric proteins |
| US6475781B1 (en) | 1990-05-17 | 2002-11-05 | Dana-Farber Cancer Institute, Inc. | Trans-dominant suppressor genes for oligomeric proteins |
| US20040087498A1 (en) * | 1991-02-28 | 2004-05-06 | Novo Nordisk Health Care Ag | Modified factor VII |
| US5833982A (en) | 1991-02-28 | 1998-11-10 | Zymogenetics, Inc. | Modified factor VII |
| US5861374A (en) * | 1991-02-28 | 1999-01-19 | Novo Nordisk A/S | Modified Factor VII |
| US5997864A (en) | 1995-06-07 | 1999-12-07 | Novo Nordisk A/S | Modified factor VII |
| US5788965A (en) * | 1991-02-28 | 1998-08-04 | Novo Nordisk A/S | Modified factor VII |
| US5817788A (en) * | 1991-02-28 | 1998-10-06 | Zymogenetics, Inc. | Modified factor VII |
| EP0575464B1 (de) * | 1991-02-28 | 2004-08-11 | Zymogenetics, Inc. | Modifizierter faktor-vii |
| US6039944A (en) * | 1992-02-28 | 2000-03-21 | Zymogenetics, Inc. | Modified Factor VII |
| PT699075E (pt) * | 1993-05-21 | 2002-05-31 | Novo Nordisk As | Factor vii modificado para inibicao de restenose vascular e de deposicao de plaquetas |
| WO1994028017A1 (en) * | 1993-06-01 | 1994-12-08 | The Scripps Research Institute | Human mutant tissue factor compositions useful as tissue factor antagonists |
| CZ334095A3 (en) * | 1993-06-18 | 1996-07-17 | Hafslund Nycomed As | Compounds containing chains of amino acids, their use and pharmaceutical compositions containing thereof |
| US5510248A (en) * | 1993-06-22 | 1996-04-23 | The University Of British Columbia | Stable recombinant meizothrombin-like polypeptides |
| US6017882A (en) * | 1997-10-23 | 2000-01-25 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US6693075B1 (en) * | 1997-10-23 | 2004-02-17 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US7247708B2 (en) | 1997-10-23 | 2007-07-24 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US6747003B1 (en) * | 1997-10-23 | 2004-06-08 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| AR017831A1 (es) * | 1997-12-10 | 2001-10-24 | Pioneer Hi Bred Int | Metodo para alterar la composicion de aminoacidos de una proteina nativa de interes, proteina elaborada, y polinucleotido |
| US6924359B1 (en) * | 1999-07-01 | 2005-08-02 | Yale University | Neovascular-targeted immunoconjugates |
| AU781618C (en) | 1999-07-02 | 2006-03-16 | Genentech Inc. | FVIIa antagonists |
| US6586574B1 (en) * | 1999-08-17 | 2003-07-01 | Nn A/S | Stabilization of freeze-dried cake |
| CN100488562C (zh) | 2000-02-11 | 2009-05-20 | 拜耳医药保健有限公司 | 凝血因子VⅡ或VⅡa样分子 |
| US20040102388A1 (en) * | 2000-03-22 | 2004-05-27 | High Katherine A. | Modified blood clotting factors and methods of use |
| US7812132B2 (en) | 2000-04-28 | 2010-10-12 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US7220837B1 (en) | 2000-04-28 | 2007-05-22 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US6905683B2 (en) * | 2000-05-03 | 2005-06-14 | Novo Nordisk Healthcare A/G | Human coagulation factor VII variants |
| US7160540B2 (en) * | 2000-06-30 | 2007-01-09 | Regents Of The University Of Minnesota | Methods for detecting activity of clottings factors |
| US6423826B1 (en) | 2000-06-30 | 2002-07-23 | Regents Of The University Of Minnesota | High molecular weight derivatives of vitamin K-dependent polypeptides |
| US20030211094A1 (en) | 2001-06-26 | 2003-11-13 | Nelsestuen Gary L. | High molecular weight derivatives of vitamin k-dependent polypeptides |
| JP4361728B2 (ja) | 2000-09-13 | 2009-11-11 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | ヒト凝固因子vii変異型 |
| US7176288B2 (en) * | 2000-09-13 | 2007-02-13 | Novo Nordisk Healthcare A/G | Human coagulation factor VII variants |
| US7615537B2 (en) * | 2000-10-25 | 2009-11-10 | Genzyme Corporation | Methods for treating blood coagulation disorders |
| AU2002218029A1 (en) * | 2000-11-09 | 2002-05-21 | The Scripps Research Institute | Modified factor viia |
| JP2004529640A (ja) | 2001-03-22 | 2004-09-30 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | 第vii凝固因子誘導体 |
| US7052868B2 (en) * | 2001-09-27 | 2006-05-30 | Novo Nordisk Healthcare A/G | Human coagulation factor VII polypeptides |
| AU2002333211B2 (en) | 2001-09-27 | 2008-05-08 | Novo Nordisk Health Care Ag | Human coagulation factor VII polypeptides |
| US7157277B2 (en) | 2001-11-28 | 2007-01-02 | Neose Technologies, Inc. | Factor VIII remodeling and glycoconjugation of Factor VIII |
| US8008252B2 (en) * | 2001-10-10 | 2011-08-30 | Novo Nordisk A/S | Factor VII: remodeling and glycoconjugation of Factor VII |
| US6960657B2 (en) * | 2001-11-02 | 2005-11-01 | Novo Nordisk Healthcare A/G | Human coagulation factor VII polypeptides |
| ES2325653T3 (es) | 2001-12-21 | 2009-09-11 | Novo Nordisk Health Care Ag | Composicion liquida de polipeptidos del factor vii. |
| KR20040065278A (ko) * | 2001-12-21 | 2004-07-21 | 노보 노르디스크 에이/에스 | 변경된 인자 ⅶ 폴리펩티드의 액체 조성물 |
| US7164002B2 (en) | 2002-02-06 | 2007-01-16 | Genentech, Inc. | FVIIa antagonists |
| MXPA04010781A (es) * | 2002-04-30 | 2005-03-07 | Maxygen Holdings Ltd | Variantes de polipeptido del factor vii o viia. |
| US20040009918A1 (en) * | 2002-05-03 | 2004-01-15 | Hanne Nedergaard | Stabilised solid compositions of modified factor VII |
| DK1517698T4 (da) * | 2002-06-21 | 2018-01-29 | Novo Nordisk Healthcare Ag | Stabiliserede faste sammensætninger af Faktor VIIa-polypeptider |
| MXPA04012496A (es) * | 2002-06-21 | 2005-09-12 | Novo Nordisk Healthcare Ag | Glicoformos del factor vii pegilados. |
| US6911323B2 (en) * | 2002-09-25 | 2005-06-28 | Novo Nordisk Healthcare A/G | Human coagulation factor VII polypeptides |
| CA2502162C (en) * | 2002-09-30 | 2014-04-15 | Bayer Healthcare Llc | Fvii or fviia variants having increased clotting activity |
| US20040176704A1 (en) * | 2003-03-04 | 2004-09-09 | Stevens Timothy A | Collection device adapted to accept cartridge for point of care system |
| BRPI0408417A (pt) | 2003-03-18 | 2006-03-21 | Novo Nordisk Healthcare Ag | métodos para a produção de um resìduo de gla purificado contendo serina protease, para a purificação de um resìduo de gla contendo serina protease e para estabilização de um resìduo de gla contendo serina protease, e, composição |
| WO2004082708A2 (en) * | 2003-03-18 | 2004-09-30 | Novo Nordisk Health Care Ag | Liquid, aqueous, pharmaceutical compositions of factor vii polypeptides |
| ES2327044T3 (es) | 2003-03-20 | 2009-10-23 | Bayer Healthcare Llc | Variantes de fvii o fviia. |
| US7897734B2 (en) * | 2003-03-26 | 2011-03-01 | Novo Nordisk Healthcare Ag | Method for the production of proteins |
| US8791070B2 (en) | 2003-04-09 | 2014-07-29 | Novo Nordisk A/S | Glycopegylated factor IX |
| KR20060015574A (ko) * | 2003-05-23 | 2006-02-17 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | 용액 중 단백질 안정화 |
| MXPA05013769A (es) * | 2003-06-19 | 2006-03-08 | Maxygen Holdings Ltd | Variantes del dominio gla del factor vii o viia. |
| JP5306597B2 (ja) * | 2003-07-01 | 2013-10-02 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | 第vii因子ポリペプチドの液体水性薬学的組成物 |
| RU2388460C2 (ru) | 2003-08-14 | 2010-05-10 | Ново Нордиск Хелс Кеа Аг | Жидкая водная фармацевтическая композиция, содержащая полипептид фактора vii |
| CN101870729A (zh) * | 2003-09-09 | 2010-10-27 | 诺和诺德医疗保健公司 | 凝固因子ⅶ多肽 |
| US20080193441A1 (en) * | 2003-11-18 | 2008-08-14 | Iconic Therapeutics, Inc. | Homogeneous Preparations of Chimeric Protein |
| US20060040856A1 (en) | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
| KR20140093711A (ko) * | 2003-12-19 | 2014-07-28 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | 인자 vii 폴리펩티드의 안정화된 조성물 |
| EP1713906A2 (de) * | 2004-02-03 | 2006-10-25 | Novo Nordisk Health Care AG | Keine funktionelle lipid-membran-bindungsdomäne aufweisende koagulationsfaktor vii/viia-varianten |
| EP1891231A4 (de) | 2005-05-25 | 2011-06-22 | Novo Nordisk As | Glykopegylierter faktor ix |
| EP2316930A1 (de) | 2005-09-14 | 2011-05-04 | Novo Nordisk Health Care AG | Menschliche Polypeptide des Koagulationfaktors VII |
| WO2007039475A1 (en) * | 2005-09-21 | 2007-04-12 | Novo Nordisk Health Care Ag | Human coagulation factor vii polypeptides |
| ES2399138T3 (es) * | 2006-03-16 | 2013-03-26 | Stellaris Pharmaceuticals Aps | Tratamiento local con factor VII |
| WO2008009635A2 (en) * | 2006-07-17 | 2008-01-24 | Novo Nordisk Health Care Ag | Factor viia analogues with increased activity for treating thrombocytopenia |
| SG174077A1 (en) * | 2007-04-13 | 2011-09-29 | Catalyst Biosciences Inc | Modified factor vii polypetides and uses thereof |
| MX2009013259A (es) | 2007-06-12 | 2010-01-25 | Novo Nordisk As | Proceso mejorado para la produccion de azucares de nucleotidos. |
| TWI465247B (zh) | 2008-04-11 | 2014-12-21 | Catalyst Biosciences Inc | 經修飾的因子vii多肽和其用途 |
| DK2440239T3 (en) | 2009-06-09 | 2017-10-16 | Prolong Pharmaceuticals Llc | HEMOGLOBIN FORMATIONS |
| TWI557135B (zh) | 2010-11-03 | 2016-11-11 | 介控生化科技公司 | 經修飾之第九因子多胜肽及其用途 |
| CN114728044A (zh) | 2019-08-15 | 2022-07-08 | 介控生化科技公司 | 用于皮下施用和按需求治疗的经修饰的因子vii多肽 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4775624A (en) * | 1985-02-08 | 1988-10-04 | Eli Lilly And Company | Vectors and compounds for expression of human protein C |
| GR860984B (en) * | 1985-04-17 | 1986-08-18 | Zymogenetics Inc | Expression of factor vii and ix activities in mammalian cells |
| ATE74164T1 (de) * | 1985-04-22 | 1992-04-15 | Genetics Inst | Herstellung mit hoher leistung des aktivfaktors ix. |
| US4959318A (en) * | 1985-06-27 | 1990-09-25 | Zymogenetics, Inc. | Expression of protein C |
| US5258288A (en) * | 1986-07-25 | 1993-11-02 | Genzyme Corporation | Vector containing DNA encoding mature human protein S |
| DK323587D0 (da) * | 1987-06-25 | 1987-06-25 | Novo Industri As | Protein |
| JP2799316B2 (ja) * | 1987-06-12 | 1998-09-17 | ヘキスト・マリオン・ルセル株式会社 | 雑種ヒトプロテインcおよびその遺伝子工学的製法 |
| US4994371A (en) * | 1987-08-28 | 1991-02-19 | Davie Earl W | DNA preparation of Christmas factor and use of DNA sequences |
| US5023236A (en) * | 1988-04-07 | 1991-06-11 | Corvas, Inc. | Factor VII/VIIA active site inhibitors |
-
1991
- 1991-01-25 WO PCT/US1991/000552 patent/WO1991011514A1/en not_active Ceased
- 1991-01-25 DE DE69131292T patent/DE69131292T2/de not_active Expired - Fee Related
- 1991-01-25 CA CA002074839A patent/CA2074839C/en not_active Expired - Fee Related
- 1991-01-25 JP JP50486391A patent/JP3330932B2/ja not_active Expired - Fee Related
- 1991-01-25 AT AT91904449T patent/ATE180834T1/de not_active IP Right Cessation
- 1991-01-25 EP EP91904449A patent/EP0521873B1/de not_active Expired - Lifetime
- 1991-01-25 AU AU73002/91A patent/AU651573B2/en not_active Ceased
-
1992
- 1992-09-21 US US07/951,295 patent/US5288629A/en not_active Expired - Lifetime
-
1993
- 1993-11-12 US US08/152,199 patent/US5824639A/en not_active Expired - Fee Related
-
2001
- 2001-12-26 JP JP2001394519A patent/JP2002247996A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2074839C (en) | 2000-11-14 |
| JP2002247996A (ja) | 2002-09-03 |
| EP0521873A1 (de) | 1993-01-13 |
| JPH05500161A (ja) | 1993-01-21 |
| AU7300291A (en) | 1991-08-21 |
| DE69131292T2 (de) | 1999-09-30 |
| EP0521873A4 (en) | 1993-05-05 |
| US5288629A (en) | 1994-02-22 |
| DE69131292D1 (de) | 1999-07-08 |
| JP3330932B2 (ja) | 2002-10-07 |
| AU651573B2 (en) | 1994-07-28 |
| EP0521873B1 (de) | 1999-06-02 |
| CA2074839A1 (en) | 1991-07-30 |
| US5824639A (en) | 1998-10-20 |
| WO1991011514A1 (en) | 1991-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE180834T1 (de) | Antikoagulierende proteine | |
| Elg et al. | Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor | |
| CA1244763A (en) | Blood coagulation inhibiting proteins, processes for preparing them and their uses | |
| JP5037331B2 (ja) | 出血性障害の処置のための第ixa因子 | |
| AU3050384A (en) | Removal of lipid containing virus in blood | |
| Bajwa et al. | Thrombin-like and fibrinolytic enzymes in the venoms from the Gaboon viper (Bitis gabonica), eastern cottonmouth moccasin (Agkistrodon p. piscivorus) and southern copperhead (Agkistrodon c. contortrix) snakes | |
| CA2060507A1 (en) | Factor xa based anticoagulant compositions | |
| Janoff et al. | Digestion of lung proteins by human leukocyte granules in vitro | |
| FI953565A7 (fi) | Uusi antikoagulanttikofaktoriaktiivisuus | |
| Aronson | Factor IX complex | |
| US5637299A (en) | Enhancement of thrombolytic therapy with deglycosylated forms of plasminogen | |
| Nagaki et al. | Inactivator of the First Component of Human Complement (CĪINA) Enhancement of CĪlNA Activity against CĪs by Acidic Mucopolysaccharides | |
| Pechet et al. | The effect of certain proteolytic enzymes on the thrombin-fibrinogen interaction | |
| Penner | Treatment of inhibitor patients with activated prothrombin complex concentrates | |
| Weinstein et al. | Enhancement of rabbit protein S anticoagulant cofactor activity in vivo by modulation of the protein S C4B binding protein interaction. | |
| US5510248A (en) | Stable recombinant meizothrombin-like polypeptides | |
| Latallo et al. | Fibrinolytic system of guinea pig serum | |
| US20260007727A1 (en) | Drug that promotes hemostasis | |
| EP0326013A3 (de) | Von menschlichem alpha-2-Plasmin-Inhibitor abgeleitete neue Proteine oder Proteine, die diesen ähnlich sind | |
| Thelin et al. | The action of thrombin on serum albumin | |
| Fasco et al. | Evidence for a warfarin‐sensitive serum factor that participates in factor x activation by lewis lung tumor cells | |
| WO2000074711A2 (en) | 10-formyltetrahydrofolate dehydrogenase as therapeutical agent | |
| SUMI et al. | Enzymatic production of acid stable trypsin-plasmin inhibitor (ASTI) in human plasma | |
| US20030186862A1 (en) | Factor VIIa compositions | |
| Gurewich et al. | A mechanism for the potentiating effect of urokinase (UK) or tissue plasminogen activator (t-PA) on clot lysis by pro-urokinase (pro-uk) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |